news

Artificial Intelligence system to help detect skin cancer

New technology being developed by researchers is using artificial intelligence to help detect melanoma skin cancer earlier…

skin

New technology being developed by researchers is using artificial intelligence (AI) to help detect melanoma skin cancer earlier.

The technology employs machine-learning software to analyse images of skin lesions and provide doctors with objective data on tell-tale biomarkers of melanoma, which is deadly if detected too late, but highly treatable if caught early.

The AI system–trained using tens of thousands of skin images and their corresponding eumelanin and haemoglobin levels–could initially reduce the number of unnecessary biopsies, a significant health-care cost. It gives doctors objective information on lesion characteristics to help them rule out melanoma before taking more invasive action. The technology could be available to doctors as early as next year.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

“This could be a very powerful tool for skin cancer clinical decision support,” said Alexander Wong, Professor of Systems Design & Engineering at Waterloo. “The more interpretable information there is, the better the decisions are.”

Currently, dermatologists largely rely on subjective visual examinations of skin lesions such as moles to decide if patients should undergo biopsies to diagnose the disease.

The new system deciphers levels of biomarker substances in lesions, adding consistent, quantitative information to assessments currently based on appearance alone. In particular, changes in the concentration and distribution of eumelanin, a chemical that gives skin its colour, and haemoglobin, a protein in red blood cells, are strong indicators of melanoma.

“There can be a huge lag time before doctors even figure out what is going on with the patient,” said Prof Wong. “Our goal is to shorten that process.”

 

Related topics
,

Related conditions

Related organisations

Leave a Reply

Your email address will not be published. Required fields are marked *